UK regulation note · O-043
Licensed, unlicensed and investigational peptides
These terms describe different legal and evidence positions. “Unlicensed” is not another word for “investigational”, and neither term proves that an online product is lawfully supplied.
A licensed medicine has a UK marketing authorisation for defined conditions of use. An unlicensed medicine lacks that authorisation but may be supplied through limited lawful routes for individual clinical need. An investigational medicinal product is being studied within a regulated clinical trial; that status is not a retail sales permission.
Status changes the questions to ask
The categories do not form a quality ranking.
| Status | What it means | What it does not mean |
|---|---|---|
| Authorised | The medicine has a UK marketing authorisation with an approved product, indication and information. | It is not automatically suitable for every person or every off-label use. |
| Unlicensed medicine | No UK marketing authorisation covers the product. Limited routes can allow supply for a patient’s special clinical need under professional responsibility. | It is not an approval, a general consumer exemption or permission for promotion. |
| Investigational medicinal product | The product is used as the tested or reference medicine in a regulated clinical trial. | “Investigational” on a shop page does not show that the product belongs to an approved trial. |
| Exempt or unclear claim | A specific exemption may apply, or the facts may be insufficient to classify the route. | A disclaimer alone does not create an exemption or settle medicine status. |
What a marketing authorisation establishes
Authorisation follows an assessment of the named product’s quality, safety and efficacy for defined uses. The product information sets conditions, warnings and other details. It does not authenticate another vial that uses the same ingredient name.
Check the product itself, including holder, strength, pharmaceutical form and authorisation details. Use the MHRA product database lookup rather than relying on a seller’s “pharma grade” or “licensed ingredient” wording.
July 2026: a pre-authorisation advertising example
On 5 August 2026, MHRA published its decision on an email that Phlo Clinic had sent to members of the public. The email invited consumers to join a waitlist for “early access” to GLP-1 weight-loss products that did not hold UK marketing authorisation for that indication when the email was issued.
MHRA considered the email promotional and applied regulation 279 of the Human Medicines Regulations 2012. Phlo confirmed that it withdrew the advertisement, that it was no longer in use and that it would comply with the regulations and MHRA guidance. This records a completed action for the named email, not an ongoing breach.
Read the MHRA Phlo Clinic decision and the versioned MHRA advertising update log.
Unlicensed supply is a narrow clinical route
UK rules can permit an unlicensed medicinal product to meet the special needs of an individual patient when an appropriate authorised medicine cannot do so. The route involves prescriber judgement and regulated manufacture, import or supply responsibilities.
That exception is not a way to bypass authorisation for convenience, cost or general demand. An online seller calling a product “unlicensed” does not show that a prescription, individual clinical need and lawful supply chain exist.
Investigational means part of a trial framework
A genuine clinical trial has a sponsor, protocol, approvals, participant information, safety reporting and product accountability. The investigational product may be unlicensed or an authorised medicine studied in a new way.
The word does not prove that any product advertised online is trial material. Trial participation should be verified through the research team and official documentation, not a retail product description.
A four-part status check
Do not let one label answer all four.
- Identify the exact product.Name, holder, strength, form and packaging should match the record.
- Check authorisation.Search MHRA Products and read the named product information.
- Identify the route.Prescription, unlicensed special, clinical trial and retail sale have different controls.
- Assess the claims.Presentation and intended function can matter even when the seller uses a disclaimer.
Read the framework these statuses sit in and why a disclaimer does not decide status.
Source ledger
Primary guidance and standards checked on 11 August 2026.
- MHRA: Phlo Clinic pre-authorisation promotion, July 2026 · MHRA considered the “early access” email promotional; Phlo confirmed that the advert was withdrawn and no longer in use.
- Human Medicines Regulations 2012 · The principal UK legal framework for human medicines.
- MHRA: supply of unlicensed medicinal products · Explains the limited “specials” route for individual clinical need and the responsibilities around supply.
- MHRA: prescriber responsibilities for off-label or unlicensed use · Unlicensed use carries added professional responsibility and does not amount to product authorisation.
- Health Research Authority: clinical trials of investigational medicinal products · Explains the regulated clinical-trial framework and current UK requirements.
- MHRA: borderline products · Medicine status can turn on presentation, claims and function, not merely the label chosen by a seller.
Follow the adjacent evidence
Questions people ask
Is an unlicensed medicine illegal in the UK?
Not necessarily. UK law allows limited unlicensed supply routes for an individual patient’s special clinical need. The route requires professional judgement and regulated supply; it is not general approval.
Is an investigational peptide approved?
Not for general marketing merely because it is investigational. The term describes its role in a regulated trial. A trial still requires the relevant sponsor, protocol and approvals.
Can a licensed ingredient make an online vial licensed?
No. A marketing authorisation applies to the exact medicinal product, including its holder, formulation, strength, manufacture and conditions. Sharing an ingredient name does not transfer the authorisation.
How do I check whether a peptide medicine is authorised?
Search the MHRA Products database and match the exact product name, strength, pharmaceutical form and authorisation holder. If those details do not match, do not treat the record as confirmation.
Does “research use only” make a product non-medicinal?
No. The MHRA considers presentation, claims, function and the full circumstances. A disclaimer cannot undo instructions, testimonials or other material that presents the product for human use.
Can an unlicensed medicine be advertised to consumers?
UK medicine advertising rules prohibit advertising an unlicensed medicine. A lawful special-supply route for an individual patient does not create permission for public promotion.
Editorial experience
From our work: how we checked this page
For topical-map item O-043, Licensed, unlicensed and investigational peptides was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 6 unique external sources and 6 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Yianni Kiromitis checked the page against its mapped purpose, verified the cited sources, reviewed the internal routes and approved the final wording as Lead Author, Publisher and Managing Editor. This page does not carry a specialist review credit because its publication decision did not require a scientific or clinical conclusion beyond the named material it links to.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.